Boswella™ Cream delivers standardized Boswellia serrata (Frankincense) extract topically via a patented liposomal delivery system. A natural 5-LOX inhibitor supporting joint comfort, healthy inflammatory response, and tissue maintenance, without the GI or renal risk profile of NSAIDs.
Boswella™ Cream is a topical formulation of standardized Boswellia serrata extract — the gum resin of the Boswellia serrata tree (Frankincense), used for centuries in Ayurvedic medicine for joint and tissue support. The bioactive constituents of Boswellia serrata — Boswellic Acids — have been shown in research to selectively inhibit 5-LOX (5-lipoxygenase), the enzyme responsible for leukotriene synthesis. By blocking leukotriene formation at the cellular level, Boswellic Acids support a healthy inflammatory response through a mechanism entirely distinct from NSAIDs and COX inhibitors.
Boswella™ Cream delivers this standardized extract topically via a patented liposomal delivery system, supporting deeper penetration into target tissues than standard cream vehicles.
| Specification | Detail |
|---|---|
| Active ingredient | Boswellia serrata standardized extract (Boswellic Acids) |
| Delivery system | Patented liposomes — natural deep penetrating |
| Net weight | 4 oz (113g) |
| Prescription required | No |
| Retail eligible | Yes |
The inflammatory cascade involves multiple enzymatic pathways. The two most clinically relevant for joint and tissue inflammation are the COX pathway (targeted by NSAIDs) and the 5-LOX pathway (targeted by Boswellic Acids).
5-LOX is a lipoxygenase enzyme that oxidizes omega-6 fatty acids to produce leukotrienes — pro-inflammatory signaling molecules involved in tissue inflammation and the degenerative processes associated with aging. The modern omega-6-dominant diet contributes to elevated 5-LOX activity by providing an excess substrate for leukotriene formation.
Boswellic Acids selectively inhibit 5-LOX, blocking leukotriene synthesis upstream of the inflammatory cascade. This mechanism is distinct from — and complementary to — COX pathway inhibition.
Why the 5-LOX pathway matters for practice: NSAIDs target COX-2 to reduce inflammation, but simultaneously block COX-1 — the enzyme that maintains gastric mucosal integrity. This off-target COX-1 inhibition is a primary driver of NSAID-associated gastrointestinal and renal side effects, serious enough that the FDA requires black box warnings on NSAIDs and COX inhibitors. Boswellic Acid inhibition of 5-LOX has no effect on COX activity, preserving the gastric lining and renal prostaglandin production while still addressing the leukotriene arm of the inflammatory response.
Standard topical creams deposit active ingredients on the skin surface, where absorption into deeper tissues is limited by the skin barrier. Boswella™ Cream uses a patented liposomal delivery system to encapsulate Boswellic Acids in lipid-bilayer vesicles that more closely mimic cell membrane structure — supporting transport across the skin barrier and into underlying tissue layers where leukotriene-mediated inflammation occurs.
For practices recommending topical joint comfort support, delivery system quality is a meaningful clinical differentiator. The liposomal vehicle is what separates a pharmaceutical-grade topical from a conventional cosmetic cream.
Non-NSAID mechanism for joint comfort support: Practices managing patients who cannot or should not use NSAIDs — due to GI history, renal considerations, cardiovascular risk, or polypharmacy — need alternatives. Boswella™ provides a mechanistically distinct option via the 5-LOX pathway without the COX inhibition risk profile.
Topical application targets the site: Applied directly to the affected joint or tissue area, Boswella™ delivers Boswellic Acids topically to the target site rather than systemically — appropriate for practices managing localized joint comfort concerns.
No prescription, retail-eligible: Boswella™ is a non-prescription supplement that can be recommended for patient use and sold directly as a retail product, creating a revenue stream alongside clinical recommendations.
Private label available: Boswella™ Cream is available under Legere’s private label program for practices building a branded product line.
DHEA 25mg Capsules — DHEA supports adrenal hormone precursors that play a role in the body’s inflammatory regulatory response. Practices addressing inflammation from a holistic hormonal standpoint may combine Boswella™ Cream topically with DHEA supplementation for broader systemic support.
GLP-1 Support Caps — For weight management practices: metabolic inflammation and adipose tissue-driven leukotriene activity are connected. Supporting healthy inflammatory response alongside GLP-1 protocols addresses both metabolic and inflammatory components of the patient’s health picture.
Sermorelin Acetate Injection — For anti-aging and longevity practices: GH support via Sermorelin and leukotriene modulation via Boswellia address complementary aspects of the cellular aging and tissue maintenance picture.
Boswellia serrata is well-tolerated and non-toxic at standard topical doses. No prescription is required.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What makes Boswella™ Cream different from standard topical pain creams?
Most topical pain products use cooling or counterirritant agents (menthol, camphor) or deliver NSAIDs transdermally — all targeting the COX pathway. Boswella™ works via the 5-LOX pathway, selectively inhibiting leukotriene synthesis through Boswellic Acids. It’s a mechanistically distinct approach, delivered via a patented liposomal system for deeper tissue penetration than standard cream vehicles.
Why is 5-LOX inhibition clinically relevant compared to COX inhibition?
COX inhibition (NSAIDs) carries GI and renal risk because it blocks both COX-2 (inflammation-relevant) and COX-1 (gastric lining maintenance). 5-LOX inhibition via Boswellic Acids addresses the leukotriene arm of the inflammatory cascade without affecting COX enzymes — and therefore without the associated gastric mucosal and renal prostaglandin risks. The FDA requires black box warnings on NSAIDs for this reason; Boswellia carries no equivalent requirement.
Is a prescription required?
No. Boswella™ Cream is a non-prescription supplement. It can be recommended to patients and sold as a retail product without a prescription.
Is private label available?
Yes. Boswella™ Cream is available through Legere’s private label program for practices building a branded product line. Contact our team for details.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Schedule a no obligation/no-pressure call to quickly increase your weight loss clinic’s revenue.
